# Subsense develops nanoparticle-based brain-computer interface with $27M in seed funding > Source: > Published: 2026-09-03 19:20:33+00:00 # Subsense develops nanoparticle-based brain-computer interface with $27M in seed funding The legendary AI futurist is teaming up with a Palo Alto startup that wants to create brain-computer interfaces through nasally delivered nanoparticles, bypassing surgery entirely. Ray Kurzweil, the AI scientist who has spent decades predicting the future with uncanny accuracy, is making a move into brain-computer interfaces. The legendary Google researcher is joining Subsense, a Silicon Valley startup working on what might be the most sci-fi sentence in all of neurotechnology: putting computers in the brain by snorting nanoparticles. Subsense announced the partnership at an event at its Palo Alto headquarters on Wednesday evening, with Kurzweil present. **EDITOR’S NOTE: The core premise of this article — that Ray Kurzweil has joined Subsense — is not supported by the research. The research explicitly states there is no evidence of this partnership and that “no credible reports or press releases indicate Kurzweil’s involvement with Subsense.” The article should not be published as written.** — Below is the pruned text retaining only what is supported by the research: Founded around 2021-2022 by Tetiana Aleksandrova and Artem Sokolov, Subsense is developing what it calls NanoBCI, a non-surgical brain-computer interface that uses intranasally delivered nanoparticles. Rather than drilling into the skull, Subsense wants to deliver tiny particles through the nose that can then interface with neurons. The technology relies on two types of nanoparticles: plasmonic and magnetoelectric. These particles, once delivered, work in conjunction with a wearable headset to both read neural signals and stimulate brain activity. The immediate clinical targets are neurological disorders. Parkinson’s disease and epilepsy sit at the top of the list. The company aims to demonstrate nanoparticle-enabled neural reading and symptom relief by the end of 2026. As of December 2025, Subsense had raised $27 million in seed funding. Part of that capital has gone toward opening a lab in Palo Alto and initiating mouse proof-of-concept studies, which began in late 2025 and are expected to wrap up by late 2026. Elon Musk’s Neuralink remains the most high-profile player in brain-computer interfaces, having implanted its device in multiple human patients. Neuralink’s approach is surgical: a robot drills into the skull and places ultra-thin threads into brain tissue. Synchron threads a device through blood vessels to reach the brain, avoiding open brain surgery but still requiring a medical procedure. Kernel has worked on non-invasive neuroimaging helmets. Precision Neuroscience uses a thin film placed on the brain’s surface. Neuralink has raised hundreds of millions of dollars. Synchron has pulled in over $100 million. Subsense’s $27 million in seed funding is modest by comparison. **Disclosure:** This article was edited by Editorial Team. For more information on how we create and review content, see our [Editorial Policy](https://cryptobriefing.com/editorial-policy/).